Price Target Changed • Jun 17
Price target increased by 8.9% to US$47.00 Up from US$43.17, the current price target is an average from 6 analysts. New target price is 8.3% above last closing price of US$43.40. Stock is up 121% over the past year. The company is forecast to post earnings per share of US$1.03 for next year compared to US$0.79 last year. Live News • May 10
Guardian Pharmacy Services Raises Outlook After Q1 Earnings Surprise and Prescription Volume Growth Guardian Pharmacy Services reported Q1 2026 revenue of $336.6 million and net income of about $13.5 million, with adjusted EPS of $0.29 coming in above analyst expectations of $0.24.
Management raised full-year 2026 revenue guidance to a range of $1.4 billion to $1.42 billion and lifted adjusted EBITDA guidance to $123 million to $127 million, which includes a $3 million one-time benefit recognized in Q1.
The company highlighted margin expansion helped by lower drug acquisition costs, a 10% rise in residents served to roughly 207,000, and prescription volume growth. Management also cited $3.2 million in legal expenses and higher labor cost expectations through 2026.
For you as an investor, the key takeaway is that Guardian Pharmacy Services is pointing to both top-line and profit metrics that management believes can support higher full-year expectations, even while dealing with a 60% decline in branded drug pricing linked to the Inflation Reduction Act. Volume growth in residents and prescriptions, along with lower acquisition costs, is helping offset pricing pressure, which is important context if you are considering earnings quality rather than just headline EPS.
The non-dilutive secondary offering in March 2026, followed by a repurchase and cancellation of shares that left the share count unchanged, also matters. It increases trading liquidity without affecting ownership percentages. At the same time, investors may want to factor in ongoing legal expenses and the expectation of modestly higher labor costs when assessing how sustainable current margins and guidance could be. Reported Earnings • May 07
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: EPS: US$0.21 (up from US$0.15 in 1Q 2025). Revenue: US$336.6m (up 2.2% from 1Q 2025). Net income: US$13.3m (up 41% from 1Q 2025). Profit margin: 3.9% (up from 2.9% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 7.7%. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Healthcare industry in the US. Announcement • Apr 15
Guardian Pharmacy Services, Inc. to Report Q1, 2026 Results on May 06, 2026 Guardian Pharmacy Services, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026 Announcement • Mar 27
Guardian Pharmacy Services, Inc., Annual General Meeting, May 05, 2026 Guardian Pharmacy Services, Inc., Annual General Meeting, May 05, 2026. Location: 8909 purdue road, suite 500, 46268, indianapolis United States Major Estimate Revision • Mar 18
Consensus EPS estimates increase by 12% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from US$0.957 to US$1.07. Revenue forecast steady at US$1.41b. Net income forecast to grow 39% next year vs 25% growth forecast for Healthcare industry in the US. Consensus price target up from US$35.00 to US$38.50. Share price was steady at US$33.91 over the past week. Reported Earnings • Mar 12
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: US$0.79 (up from US$1.78 loss in FY 2024). Revenue: US$1.45b (up 18% from FY 2024). Net income: US$49.2m (up US$159.3m from FY 2024). Profit margin: 3.4% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 16%. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Healthcare industry in the US. Price Target Changed • Mar 12
Price target increased by 9.6% to US$37.25 Up from US$34.00, the current price target is an average from 4 analysts. New target price is 12% above last closing price of US$33.27. Stock is up 72% over the past year. The company is forecast to post earnings per share of US$1.03 for next year compared to US$0.79 last year. Announcement • Mar 12
Guardian Pharmacy Services, Inc. Updates Earnings Guidance for the Full Year 2026 Guardian Pharmacy Services, Inc. updated earnings guidance for the full year 2026. For the year, the company expects revenue of $1.40 billion – $1.42 billion compared to previous guidance of $1.40 billion – $1.42 billion. Announcement • Feb 10
Guardian Pharmacy Services, Inc. to Report Q4, 2025 Results on Mar 11, 2026 Guardian Pharmacy Services, Inc. announced that they will report Q4, 2025 results After-Market on Mar 11, 2026 Announcement • Jan 15
Guardian Pharmacy Services, Inc. Reiterates Earnings Guidance for 2025 and Provides Earnings Guidance for 2026 Guardian Pharmacy Services, Inc. reiterated earnings guidance for 2025 and provides earnings guidance for 2026. For 2025, the company expects revenue to be in the range of $1.43 billion to $1.45 billion.
For 2026, the company expects revenue to be in the range of $1.40 billion to $1.42 billion. Reported Earnings • Nov 11
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: EPS: US$0.16 (up from US$2.00 loss in 3Q 2024). Revenue: US$377.4m (up 20% from 3Q 2024). Net income: US$9.82m (up US$131.8m from 3Q 2024). Profit margin: 2.6% (up from net loss in 3Q 2024). Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Healthcare industry in the US. Price Target Changed • Nov 11
Price target increased by 11% to US$30.25 Up from US$27.33, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of US$31.25. Stock is up 41% over the past year. The company is forecast to post earnings per share of US$0.66 next year compared to a net loss per share of US$1.77 last year. Announcement • Nov 11
Guardian Pharmacy Services, Inc. Updates Earnings Guidance for the Year 2025 Guardian Pharmacy Services, Inc. updated earnings guidance for the year 2025. For the year, the company now expects Revenue of $1.43 billion - $1.45 billion against previous guidance of $1.39 billion - $1.41 billion. Announcement • Oct 06
Guardian Pharmacy Services, Inc. to Report Q3, 2025 Results on Nov 10, 2025 Guardian Pharmacy Services, Inc. announced that they will report Q3, 2025 results After-Market on Nov 10, 2025 Reported Earnings • Aug 12
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2025 results: EPS: US$0.15. Revenue: US$344.3m (up 15% from 2Q 2024). Net income: US$9.03m (down 15% from 2Q 2024). Profit margin: 2.6% (down from 3.5% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.9%. Earnings per share (EPS) missed analyst estimates by 9.7%. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in the US. Announcement • Aug 12
Guardian Pharmacy Services, Inc. Raises Earnings Guidance for the Full Year 2025 Guardian Pharmacy Services, Inc. updated earnings guidance for the full year 2025. For the year, the company expects revenue to be in the range of $1.39 billion - $1.41 billion compared to previous guidance of $1.33 billion - $1.35 billion . Announcement • Aug 05
Guardian Pharmacy Services, Inc. (NYSE:GRDN) acquired Managed Healthcare Pharmacy. Guardian Pharmacy Services, Inc. (NYSE:GRDN) acquired Managed Healthcare Pharmacy on August 4, 2025. Following the acquisition, Managed Healthcare Pharmacy will continue operating under its existing name and all existing leadership and staff will remain in place.
Guardian Pharmacy Services, Inc. (NYSE:GRDN) completed the acquisition of Managed Healthcare Pharmacy on August 4, 2025. Announcement • Jul 23
Guardian Pharmacy Services, Inc. to Report Q2, 2025 Results on Aug 11, 2025 Guardian Pharmacy Services, Inc. announced that they will report Q2, 2025 results After-Market on Aug 11, 2025 Announcement • Jun 03
Guardian Pharmacy Services, Inc. (NYSE:GRDN) acquired Mercury Pharmacy Services Inc. Guardian Pharmacy Services, Inc. (NYSE:GRDN) acquired Mercury Pharmacy Services Inc. on June 2, 2025.
Guardian Pharmacy Services, Inc. (NYSE:GRDN) completed the acquisition of Mercury Pharmacy Services Inc. on June 2, 2025. Announcement • May 23
Guardian Pharmacy Services, Inc. has completed a Follow-on Equity Offering in the amount of $157.5 million. Guardian Pharmacy Services, Inc. has completed a Follow-on Equity Offering in the amount of $157.5 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 7,500,000
Price\Range: $21
Discount Per Security: $0.84 Announcement • May 21
Guardian Pharmacy Services, Inc. has filed a Follow-on Equity Offering. Guardian Pharmacy Services, Inc. has filed a Follow-on Equity Offering.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 7,500,000 Buy Or Sell Opportunity • May 19
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 32% to US$26.52. The fair value is estimated to be US$21.77, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Reported Earnings • May 13
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2025 results: EPS: US$0.15. Revenue: US$329.3m (up 14% from 1Q 2024). Net income: US$9.45m (up 41% from 1Q 2024). Profit margin: 2.9% (up from 2.3% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 17%. Revenue is forecast to grow 3.6% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in the US. Announcement • May 09
Guardian Pharmacy Services, Inc. Appoints Ashley Ragsdale Stockton as Head of Investor Relations Guardian Pharmacy Services, Inc. announced the appointment of Ashley Stockton as Senior Director, Head of Investor Relations. She will be responsible for leading the investor relations strategy and serving as the primary liaison with shareholders, analysts, and the broader investment community. Ashley joins Guardian with nearly thirty years of experience in equity markets. Most recently, she served as Head of Southeast Institutional Equity Sales for J.P. Morgan, where she built and managed strategic partnerships with institutional investors, delivering differentiated research insights and strategic access to capital markets. Earlier in her career, Ashley was an equity research associate across several sectors and held a strategic marketing role in investment banking in New York. Her breadth of experience has equipped her with a strong, multi-dimensional foundation across finance, investor communications, and capital markets. Stockton holds a Bachelor of Science from the McIntire School of Commerce at the University of Virginia. She currently serves on the board of the Georgia Securities Association. Announcement • May 01
Guardian Pharmacy Services, Inc. to Report Q1, 2025 Results on May 12, 2025 Guardian Pharmacy Services, Inc. announced that they will report Q1, 2025 results After-Market on May 12, 2025 Announcement • Mar 31
Guardian Pharmacy Services, Inc., Annual General Meeting, May 09, 2025 Guardian Pharmacy Services, Inc., Annual General Meeting, May 09, 2025. Location: at 8909 purdue road, suite 500, in 46268, indianapolis United States Reported Earnings • Mar 27
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: US$1.41 loss per share. Revenue: US$1.23b (up 17% from FY 2023). Net loss: US$87.3m (down 465% from profit in FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 48%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in the US. Reported Earnings • Nov 14
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2024 results: US$1.84 loss per share. Revenue: US$314.4m (up 16% from 3Q 2023). Net loss: US$112.6m (down US$113.0m from profit in 3Q 2023). Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Consumer Retailing industry in the US. Announcement • Nov 13
Guardian Pharmacy Services, Inc. Provides Financial Guidance for the Full Year 2024 Guardian Pharmacy Services, Inc. provided financial guidance for the full year 2024. For the year, the company expects revenue of $1.205 billion to $1.215 billion. Announcement • Oct 30
Guardian Pharmacy Services, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Guardian Pharmacy Services, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024 Announcement • Sep 27
Guardian Pharmacy Services, Inc. has completed an IPO in the amount of $112 million. Guardian Pharmacy Services, Inc. has completed an IPO in the amount of $112 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 8,000,000
Price\Range: $14
Discount Per Security: $0.98
Transaction Features: Reserved Share Offering; Sponsor Backed Offering Board Change • Sep 25
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.